General description
Quasi-orthogonally-protected Lys derivative. The Fmoc group can be removed selectively by treatment with piperidine; the Dde group is cleaved with 2% hydrazine in DMF [1]. When removing Dde in the presence of allyl-based protecting groups, allyl alcohol should be included in the deprotection solution to prevent reduction of the allyl group [2]. Also available Fmoc-Lys(Dde)-OH 852057. This derivative has been employed in Fmoc SPPS to facilitate the introduction of biotin to the side-chain of lysine [3].
Associated Protocols and Technical Articles
Guide to Selection of Orthogonally-Protected Building Blocks for Fmoc SPPS
Literature references
[1] B. W. Bycroft, et al. (1993) J. Chem. Soc., Chem. Commun., 778.
[2] B. Rohwedder, et al. (1998) Tetrahedron Lett., 39, 1175.
[3] J. Mack, et al. (1999) Lett. Pept. Sci., 6, 135.
Linkage
Replaces: 04-12-5201
Analysis Note
Colour (visual): white to slight yellow to beige
Appearance of substance (visual): powder
Identity (IR): passes test
Enantiomeric purity: ≥ 99.5 % (a/a)
Purity (TLC(157B)): ≥ 97 %
Purity (TLC(CMA2)): ≥ 97 %
Assay (HPLC, area%): ≥ 96.0 % (a/a)
Solubility (1 mmole in 2 ml DMF): clearly soluble
Assay (acidimetric): ≥ 90.0 %
Water (K. F.): ≤ 1.00 %
To see the solvent systems used for TLC of Novabiochem® products please click here.
Legal Information
Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany
Molecular Weight: 532.63. Empirical Formula: C31H36N2O6. Quality Level: 200. product line: Novabiochem®. . Assay: ≥. 90.0% (acidimetric), ≥. 96.0% (HPLC), ≥. 97% (TLC). form: powder. reaction suitability: reaction type: Fmoc solid-phase peptide synthesis. manufacturer/tradename: Novabiochem®. . mp: >. 70 . °C (decomposition). application(s): peptide synthesis. functional group: amine. storage temp.: 15-25°C. Storage Class Code: 11 - Combustible Solids. WGK: WGK 2. Flash Point(F): Not applicable. Flash Point(C): Not applicable.- UPC:
- 12141802
- Condition:
- New
- HazmatClass:
- No
- MPN:
- 8540000001
- CAS:
- 156648-40-7
akash.verma@cenmed.com
(732) 447-1115





